Redeye initiates coverage of OEM International, a niche acquirer of technology trading SMEs that has...
Redeye leaves a comment following Klaria’s recent announcement of a licensing agreement with CNX The...
Henrik Andersson, who has served as CEO of Northbaze since 2018, has informed the board of directors...
Redeye comments on yesterday’s news from FMG, where it expects to be negatively impacted by reduced ...
Redeye comments on SynAct’s successful rights issue.
Taaleri announced today 9 January, that its CEO Peter Ramsay has resigned and will leave his positio...
Redeye provides a comment on Xspray following yesterday's press release announcing a delay in the re...
Redeye provides a short comment on the trading update from Cheffelo released earlier this morning.
Redeye retains its Q4 and 2025 forecasts for Transtema.
Q4 report due 11 February We forecast Q4 net sales of SEK 520m & EBITA of SEK 78m We reiterate our f...
Redeye comments on Sivers Semiconductors’ announcement of a new USD5.
Redeye comments on the new data from the triple combination study of BI-1206 and the phase I monothe...
Redeye comments on the organisational changes and their implications on forecasts and makes a previe...
All share offer of SEK 58.7/sh accepted, delisting approved More about Tethys and the offer All sha...
Sells Ofir to Jobindex for DKK 20m, or ~DKK 1.0/share.
Q4 number of subsscribers 2% above ABGSCe driven by premium The beat would lift service revenue by N...
Smart Eye has announced an agreement to license iris recognition technology from Fingerprint Cards f...
Solid Q4e ahead, likely to end '24e with a fifth guidance upgrade Market conditions appear unchanged...
Redeye comments on announcing a new pilot involving the renowned Mayo Clinic.
Redeye leaves a comment on Xbrane’s press release stating that it now has re-submitted its Lucentis ...
